Skip to content
العربية

Science · Ingredient

Minoxidil

Hair-growth stimulant (potassium-channel opener)

Hair-root supportHair & Scalp

Ingredient profiles describe what an ingredient is and why it is used in formulations. They are not efficacy claims.

What it is

The original clinically proven topical treatment for hereditary hair loss.

What it does

It wakes resting hair follicles and helps them grow thicker hair that stays longer. Left on the scalp as a spray it works longest; in a shampoo it brings the same active into your daily wash.

Evidence

Hair-growth stimulant. In the follicle it is converted to minoxidil sulphate, a potassium-channel opener; topically it shortens telogen, triggers early entry into anagen, may prolong anagen and enlarges follicles, although the exact follicular mechanism is not fully established. In a 48-week randomised trial in men with androgenetic alopecia, 5% topical minoxidil produced significantly more regrowth than 2% or placebo, with an earlier response. In women with female pattern hair loss, a 48-week randomised trial found both 2% and 5% topical solutions superior to placebo. Benefit depends on continued use and regresses after stopping. Leave-on solutions, sprays and foams carry the main clinical evidence; in a rinse-off shampoo the contact time is short, so a minoxidil shampoo fits best as the washing step of a routine built around a leave-on minoxidil product. The most common effects are local irritation, itching and dryness, a temporary increase in shedding in the first weeks, and unwanted facial hair, more often in women. In leave-on serums minoxidil 5% is applied twice daily for androgenetic alopecia in men and, with medical advice, in women. In women, 5% solution was superior to placebo on all primary end points but caused more pruritus, local irritation and hypertrichosis than 2% (Lucky 2004), and 5% foam once daily was non-inferior to 2% solution twice daily (Blume-Peytavi 2011). Off-label, a small 16-week placebo-controlled trial in men found more beard growth with 3% minoxidil lotion (Ingprasert 2016). Liposomal and other nanocarrier systems increased follicular deposition and skin retention about 2- to more than 7-fold versus conventional solutions in preclinical studies (Jain 2010; Copesco 2026), but clinical superiority in patients has not yet been shown.

References 9
  1. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. doi:10.1067/mjd.2002.124088. PMID 12196747.
  2. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. doi:10.1016/j.jaad.2003.06.014. PMID 15034503.
  3. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-94. doi:10.1111/j.1365-2133.2004.05785.x. PMID 14996087.
  4. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786. doi:10.2147/DDDT.S214907. PMID 31496654.
  5. Rossi A, Cantisani C, Melis L, et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-6. doi:10.2174/187221312800166859. PMID 22409453.
  6. Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.e2. doi:10.1016/j.jaad.2010.09.724. PMID 21700360.
  7. Ingprasert S, Tanglertsampan C, Tangphianphan N, et al. Efficacy and safety of minoxidil 3% lotion for beard enhancement: a randomized, double-masked, placebo-controlled study. J Dermatol. 2016;43(8):968-9. doi:10.1111/1346-8138.13312. PMID 26893270.
  8. Jain B, Singh B, Katare OP, Vyas SP. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res. 2010;20(2):105-14. doi:10.1080/08982100903161449. PMID 19698000.
  9. Copesco HDRP, Albertino GS, Lima FR, et al. Nanocarriers for topical minoxidil in androgenetic alopecia: systematic review of preclinical and clinical evidence. An Bras Dermatol. 2026;101(4):501400. doi:10.1016/j.abd.2026.501400. PMID 42398233.

Riviera products

Products that list this ingredient

Solutions

Related concerns